Dr. Reddy’s Laboratories reported consolidated revenues of ₹8,805 crore in Q2FY26, up 9.8% year-on-year and 3% sequentially. Profit after tax rose 14% to ₹1,437 crore, while EBITDA stood at ₹2,351 crore with a margin of 26.7%. Gross margins eased to 54.7% due to lower Lenalidomide sales and pricing pressure in the U.S. market. The company completed the Stugeron acquisition across 18 markets, launched two gastrointestinal drugs in India, and made progress on its Semaglutide and denosumab biosimilar pipeline. With Europe and emerging markets driving growth, Dr. Reddy’s remains focused on selective expansion and prudent capital use.

See Full Page